Type 2 diabetes is associated with excess mortality ([@B1]), higher health care costs ([@B2]), and reduced quality of life ([@B3]). The clinical antecedents of diabetes-related complications include poor glucose control, hypertension, and dyslipidemia, which result in a requirement for a combination of preventative or remedial strategies. While treatment efficacy for blood pressure and cholesterol levels has improved in recent years, glucose control has improved little ([@B2]). A recent study in the U.S. finds that only 13.2% of people with diabetes achieved target levels for all three risk factors ([@B4]).

Although the choice of treatment regimen and the specific glucose-control target at a population level remains contentious ([@B5]), it is clear that an individual's failure to use prescribed medications properly---in terms of adherence and/or persistence---also contributes to adverse clinical outcomes. On average, half the patients prescribed medications for modifiable risk factors common to people with diabetes discontinue therapy within 12 months of treatment initiation ([@B6]). Poorly compliant patients miss scheduled appointments for diabetes-related monitoring and treatment ([@B7]), and this is associated with poor glucose control ([@B7],[@B8]).

Insulin is widely recognized as the most efficacious treatment for patients with type 2 diabetes ([@B9]), but successful treatment additionally requires regular blood glucose monitoring and insulin titration ([@B10]). The effects of treatment noncompliance in this patient population, therefore, may be expected to have a more dramatic impact on clinical outcomes.

The purpose of this study was to determine if poor medication compliance and/or nonattendance at scheduled medical appointments, as assessed by primary care providers or their staff during routine care, was associated with all-cause mortality in people with type 2 diabetes receiving insulin.

RESEARCH DESIGN AND METHODS {#s2}
===========================

Data source {#s3}
-----------

Data were extracted from The Health Improvement Network (THIN) database ([@B11]), a longitudinal, anonymized research database derived from \>350 primary care practices in the U.K. The THIN database presently contains records for \>8 million patients, of whom ∼4 million are actively registered and can be followed prospectively ([@B12]). Available data include patient demographics, medical history (including diagnoses and health contacts), biochemistry and microbiology test results, and pharmaceutical prescriptions.

Read codes {#s4}
----------

Read codes are standardized codes used to record clinical data on computerized systems in primary care in the U.K. ([@B13]) and are routinely used to evaluate and reward practices' performance in relation to national treatment targets according to the Quality Outcomes Framework ([@B14]). These Read codes are cross-mapped to ICD-9 and ICD-10 (for diseases); and Office of Population, Censuses, and Surveys Classification of Surgical Operations and Procedures (OPCS)-4 (for procedures); and the British National Formulary (for medications). There are also many additional codes for data items, such as family history, occupation, adverse events, and social factors, as well as for medication compliance and appointment attendance. In most cases, the physician (or nurse for nurse-led consultations) recorded the codes at the time of the consultation. Administrative staff sometimes recorded other data, for example, data transcribed from letters from hospital consultants. The physician or nurse assessed medication noncompliance at the time of consultation based on assessment of the patient. This is a subjective measure based primarily on the physician's assessment at consultation (or transcribed from letters from hospital consultants). Contact nonattendance was recorded when the patient failed to attend a scheduled appointment at the primary care practice or information was fed back (via letter) that a patient had not attended a hospital appointment. This is an objective measure, though its application might not be uniform or systematic.

The diagnostic information in the THIN database is recorded using the Read code vocabulary.

Patient selection and coding of diabetes type {#s5}
---------------------------------------------

Patients were selected for the study if they had Read codes exclusively and explicitly indicative of type 2 diabetes. Where no specific type of diabetes was recorded or where, in a small number of instances, the patient history contained conflicting type 1 and type 2 codes, patients were classified as having type 2 diabetes if they had at least one record with a Read code indicative of type 2 diabetes and at least one prescription for an oral antidiabetic agent or if they had been prescribed two different classes of oral antidiabetic medication. Patients were excluded if they were aged \<35 years at presentation and initiated on insulin with no prescriptions for any oral antidiabetic agents. Patients with secondary diabetes were also excluded.

Patients were required to have at least 36 months of care and follow-up before the mortality observation period, including at least 6 months of observation prior to their initiation of insulin therapy (a wash-in period), and at least 30 months of treatment with insulin during which their compliance could be assessed. Mortality was assessed from the end of the 36-month assessment period, which was defined as the index date. Patients with an index date between January 2000 and November 2009 were extracted for analysis, resulting in a study population of 15,984. All patients were observed until death or data censorship (median \[IQR\] observation period = 3.16 years \[1.50--5.37\]).

Classification of treatment noncompliance {#s6}
-----------------------------------------

In each cohort, patients were observed for an initial 30-month period during which their treatment noncompliance was determined. Specific Read codes within the dataset were used to characterize patients with respect to medication noncompliance and nonattendance at a primary care or hospital scheduled contact. Medication noncompliance was defined as noncompliance to any prescribed medication, including but not limited to diabetes medication. An episode of medication noncompliance or contact nonattendance was defined for each unique Read code occurring on each single day. Medication compliance was defined as a binary variable (no noncompliance Read codes vs. at least one noncompliance Read code). Contact attendance was classified as no nonattendance and two categories of noncompliance (from one to two missed appointments and greater than two missed appointments).

The use of the term *noncompliance* as opposed to *nonadherence* is intentional and reflects the nomenclature present in the Read codes.

Statistical analysis {#s7}
--------------------

Index date characteristics of compliance groups were compared using univariate statistics (ANOVA for continuous variables and χ^2^ for categorical variables). Relative survival in terms of the hazard of death for treatment compliant and noncompliant patients was assessed by determining the adjusted progression to all-cause mortality and evaluated with Cox proportional hazards models with forward manual inclusion (threshold statistical significance was *P* ≤ 0.05) using SPSS version 18. The Cox proportional hazards model could include the following covariates assessed at index date (all were available and tested for inclusion in the model): age, sex, clinical values (BMI, HbA~1c~, cholesterol, and blood pressure), smoking status, and morbidity, which was represented by binary variables for history of large vessel disease, renal disease, and visual disorders and by the Charlson Index ([@B13]). Also eligible for inclusion was a continuous variable quantifying the total number of primary care contacts in the year before index date. Ethnicity and social status could not be included because this information was not recorded. The survival model also included interaction terms to determine whether medication noncompliance and contact nonattendance had nonadditive associations with mortality.

Hazard ratios (HRs) are given with 95% CIs. Case subjects with missing data were excluded from the survival model, resulting in an analytic sample of 13,401 patients.

RESULTS {#s8}
=======

Patient characteristics at index date {#s9}
-------------------------------------

The number of missed appointments (as indicated by the number of times that a visit nonattendance Read code was used) ranged from 0 to 39 in the entire cohort. The number of patients missing at least one scheduled appointment during the assessment period was 6,227 (39.0%), of whom 4,346 missed from one to two appointments and 1,881 missed more than two appointments. The number of patients identified as noncompliant with medication was 705 (4.4%). Of those patients missing one or more scheduled appointments, 423 (2.6% of the entire cohort and 6.8% of those who missed more than one appointment) also were identified as noncompliant with medication. Appointment nonattendance was higher among those who were noncompliant with medication than those who were compliant with medication (odds ratio 2.45 \[95% CI 2.099--2.857\]).

[Table 1](#T1){ref-type="table"} shows the univariate associations between index date patient characteristics and both forms of treatment noncompliance. Compared with clinic attenders, clinic nonattenders were more likely to be smokers and younger and to have higher HbA~1c~, more prior primary care contacts, and higher Charlson morbidity scores (all *P* \< 0.001). Compared with medication compliers, medication noncompliers were more likely to be women (*P =* 0.001) and smokers (*P =* 0.014) and to have higher HbA~1c~ (*P \<* 0.001), more prior primary care contacts (*P \<* 0.001), and higher Charlson morbidity scores (*P \<* 0.001).
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Index date characteristics according to diagnosis of medication noncompliance and clinic nonattendance
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Mortality {#s10}
---------

The crude, unadjusted mortality rates were greater for those patients who were noncompliant for medication or clinic attendance ([Table 2](#T2){ref-type="table"}). Findings from the Cox regression analyses are presented in [Table 3](#T3){ref-type="table"}. After adjustment for confounding factors, the diagnosis of medication noncompliance increased the hazard for mortality significantly (HR 1.58 \[95% CI 1.17--2.14\]). Clinic nonattendance was associated with increased mortality hazard of 1.16 (1.04--1.30) for those missing one to two appointments and 1.61 (1.36--1.90) for those missing two or more appointments. There was a significant interaction between nonattendance and medication noncompliance. The interaction represents the fact that the group with both risk factors has a significantly lower risk than it would have if the effects were additive. That is, the group with both risk factors is not at significantly higher risk than that with only one risk factor, whereas it would be significantly higher if the main effects were additive. To specify the nature of this interaction, we conducted an ancillary analysis. Among those who were medication compliant, there was a significant (*P* \< 0.001) monotonic increase in mortality as nonattendance increased; among those who were medication noncompliant, there was no significant difference in mortality as nonattendance increased (*P* = 0.489).
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Number of death events, length of follow-up periods, crude event rates, and crude relative risks

![](1279tbl2)

###### 

Multivariate Cox regression model of all-cause mortality (*N* = 13,401)\*
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A sensitivity analysis was performed for patients with a minimum of 1 month's survival; both indicators of treatment noncompliance remained significantly associated with mortality.

CONCLUSIONS {#s11}
===========

The principal finding of this study was that two measures of treatment noncompliance made by primary care physicians or their staff as a part of routine clinical care (i.e., a primary care physician's diagnosis of medication noncompliance and visit nonattendance) were independently associated with increased mortality in insulin-treated patients with type 2 diabetes, after controlling for clinical factors known to be associated with mortality. Although patients defined as noncompliant by either metric were more likely to smoke and have higher BMI, HbA~1c~, and morbidity at index date, the association of treatment noncompliance with subsequent mortality was independent of these risk factors. Furthermore, there was a dose-response relationship between level of missed appointments and mortality risk. Finally, there was a significant interaction between forms of treatment noncompliance involving a negative synergy in which the effect of one form of treatment noncompliance was reduced in the presence of the other form of noncompliance.

These findings can be compared with those of prior studies. Karter et al. ([@B7]) reported that missing scheduled medical appointments was associated with higher HbA~1c~ levels---a predictor of mortality---and with poor oral medication refill adherence. Rhee et al. ([@B8]) found that appointment keeping and medication adherence were each independently associated with HbA~1c~ levels and that those with both risk factors had the highest HbA~1c~ levels. As far as the authors are aware, however, our study is the first to demonstrate independent, prospective associations of medication noncompliance and clinic nonattendance with mortality. Although it was not possible to examine potential mechanisms accounting for these associations, it is likely that treatment noncompliance prior to index date resulted in increases in the number and severity of complications over time and, in turn, increased mortality.

While the associations of mortality with medication noncompliance and clinic nonattendance are independent, they are not additive. We cannot offer a definitive explanation of this lack of additivity, but it appears that patients who take their medication as prescribed benefit from increased provider supervision (fewer missed visits) while those who do not take their medication as prescribed do not benefit from increased supervision, perhaps because they are noncompliant with other (nonmedication) provider directives. Further research is needed to confirm these findings and to examine possible explanations.

Although there has been little research demonstrating that assessment of treatment noncompliance by primary care physicians can identify patients who are at increased mortality risk, one study reports that primary care physicians' assessment of patient compliance predicted mortality in patients with type 2 diabetes ([@B15]). In that study, compliance was assessed as part of a research protocol that asked for an assessment outside the routine delivery of care, based on training provided during the study. Our research goes beyond this earlier study to show that assessments made during routine clinical care by unselected primary care providers without special training in compliance assessment are also able to identify diabetic patients at significantly increased risk of mortality. These assessments of noncompliance predicted mortality even when controlling for initial levels of several physiological factors by which compliance might affect mortality (for example, comorbidity and metabolic control).

There are also very limited data available investigating the reasons underlying patient nonattendance at medical appointments, particularly in the field of diabetes. In a study of nonattendance at a family practice in Mexico City among patients with type 2 diabetes or hypertension or attending antenatal care, there were approximately equal numbers of patients either forgetting appointments or having experienced administrative problems ([@B16]), suggesting that organizational procedures may be significant contributing factors. In another study ([@B17]), providing patients with sufficient information reduced new patient nonattendance from 15 to almost 1% in a specialist diabetes clinic in the U.K. In the current study, we report considerably higher nonattendance rates of 39% during a 30-month period. Possible reasons for the discrepancy might be differences in patient-perceived value between attending a specialist versus a primary care clinic appointment or between initial versus follow-up clinic appointments. Whatever the cause, having ∼40% of patients miss at least one appointment represents both a substantial waste of health care resources and a risk for poor health outcomes.

This study has several strengths. These include the large study samples of patients with type 2 diabetes and providers who treat and diagnose these patients. The study included a wash-in period to assess patient treatment history and a lengthy period during which treatment noncompliance could be assessed. The observed findings with respect to patient age, BMI, HbA~1c~, and current smoking across the compliance categories are also consistent with previous reports ([@B18]--[@B20]). Finally, the study was able to assess the ultimate patient-relevant outcome: mortality.

This study also has limitations. The Read codes used to identify patients who were medication noncompliant are subjective. Other methods, such as biological testing of fluid or tissue samples, and more practical methods, such as pill counts, more accurately determine whether patients are complying with their recommended medication. In a similar manner, while nonattendance may be considered objective, it is not clear whether all primary care practices or individual physicians or their staff record nonattendance with the same thoroughness.

In addition, while we believe that our general conclusions are valid, any interpretation needs to consider potential pitfalls common in this type of epidemiological study, such as unmeasured confounders. For example, ethnicity and social status could not be included in this analysis, and it is plausible that these factors are common to those patients who are both noncompliant and have reduced survival. However, the analyses controlled for a large number of other demographic and medical factors that might account for the relationship between treatment noncompliance and mortality. In the current study, it was not possible to perform the analysis with compliance as a time-varying factor because of the way in which the data were recorded in the THIN database. Compliance may change over time; however, the effect of patients switching between compliance and noncompliance would be expected to make both groups more similar and, thus, the reported HR is likely to be a conservative estimate. Finally, it was not possible to examine whether treatment noncompliance was associated with deterioration in glucose control and increased morbidity over time and whether this accounted for the prospective association between treatment noncompliance and mortality.

Treatment noncompliance is being increasingly recognized as one of the major limitations to improving health care outcomes, and a greater understanding of the relationships between noncompliance and treatment practices will be important in guiding future care practices and medication development. Polypharmacy and increased frequency and complexity of medication administration are known to be associated with higher rates of medication noncompliance ([@B21],[@B22]).

The diagnostic, prescriptive, and procedural accuracy of Read codes in the U.K. has been determined previously ([@B23]); however, the practices through which health care professionals assign the codes defining medication noncompliance are yet to be determined. Diagnoses of noncompliance may be used to exclude patients from the pay-for-performance assessment used in the U.K. ([@B14]). The threat of an audit for practices reporting higher rates of patient noncompliance may mean that only those patients where there is a significant, ongoing, and noticeable problem are diagnosed as such. It is highly likely, therefore, that many more patients than those reported in this study were noncompliant with their medications. It is arguable that if this diagnosis were disengaged from financial remuneration, we would be better able to evaluate the impact of noncompliance on treatment targets and health care outcomes.

The approach used in this study appears to be easily adaptable for use in general clinical practice. Patients could be flagged for follow-up when they have missed one or more visits or are thought by the primary care physician to be noncompliant with their medication regimen (the compliance indicators associated with increased mortality in the current study). With greater attention to coding treatment noncompliance, physicians might be able to identify more patients who have elevated mortality risk and intervene to reduce noncompliance. Moreover, if future research shows a similar association between treatment noncompliance and mortality in nondiabetic populations, this approach may have broader applicability.

With currently available treatments, medication noncompliance and clinic nonattendance were associated with increased all-cause mortality in patients with insulin-treated type 2 diabetes. These associations were independent of each other and the mortality risk associated with suboptimal control of routinely targeted metabolic control parameters. Understanding and addressing factors that promote patient noncompliance will be important if we are to improve the life expectancy of patients with insulin-treated type 2 diabetes.
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